The Experience of Receiving Dexamethasone during Adolescence
Research type
Research Study
Full title
The experience of receiving dexamethasone during treatment for acute lymphoblastic leukaemia and lymphoblastic lymphoma in adolescence. A qualitative study.
IRAS ID
198060
Contact name
Katherine Durka
Contact email
Sponsor organisation
University of Oxford
Duration of Study in the UK
0 years, 10 months, 30 days
Research summary
This study aims to address the following research question: What is the experience of adolescents who have received dexamethasone during treatment for acute lymphoblastic leukaemia or lymphoblastic lymphoma? Dexamethasone is a steroid treatment which is used as part of the treatment protocol for the cancers, acute lymphoblastic leukaemia or lymphoblastic lymphoma. This steroid has been shown to have adverse side effects which can impact on quality of life. Participants aged 16-21 years old who have received dexamethasone within the last 5 years as part of their treatment for acute lymphoblastic leukaemia or lymphoblastic lymphoma would be eligible to participate. Participants will need to be in remission (without recurrence of cancer) and not be undergoing active treatment using dexamethasone at the time of participation. Eligible participants will be contacted via their hospital site of treatment and an advertisement will also be placed at hospital clinics and waiting rooms, with associated cancer support services and charities, and online via cancer charities and organisations and social media. Participants will be asked to speak to a researcher about their experiences, which would last for approximately 90mins. It is hoped that this study will improve our understanding of the experience of adolescents receiving this steroid as part of their treatment to improve the quality of care provided.
REC name
South Central - Oxford B Research Ethics Committee
REC reference
16/SC/0512
Date of REC Opinion
22 Nov 2016
REC opinion
Further Information Favourable Opinion